NAD(+) supplementation as a novel approach to cURIng HCC?

Ingmar Mederacke; Robert F Schwabe

doi:10.1016/j.ccell.2014.11.011

NAD(+) supplementation as a novel approach to cURIng HCC?

Cancer Cell. 2014 Dec 8;26(6):777-778. doi: 10.1016/j.ccell.2014.11.011.

Authors

Ingmar Mederacke¹, Robert F Schwabe²

Affiliations

¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
² Department of Medicine, Columbia University, College of Physicians & Surgeons, 1150 St. Nicolas Avenue, New York, NY 10032, USA; Institute of Human Nutrition, Columbia University, College of Physicians & Surgeons, 1150 St. Nicolas Avenue, New York, NY 10032, USA. Electronic address: [email protected].

PMID: 25490440
DOI: 10.1016/j.ccell.2014.11.011

Abstract

In this issue of Cancer Cell, Tummala and colleagues demonstrate that unconventional prefoldin RPB5 interactor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD(+)) metabolism. The results suggest that supplementation of NAD(+) may be a prophylactic or therapeutic approach in HCC.

Publication types

Comment

MeSH terms

Animals
Carcinoma, Hepatocellular / pathology*
DNA Damage*
Humans
Intracellular Signaling Peptides and Proteins / metabolism*
Liver Neoplasms / pathology*
NAD / metabolism*
Repressor Proteins / metabolism*

Substances

Intracellular Signaling Peptides and Proteins
Repressor Proteins
URI1 protein, human
Uri1 protein, mouse
NAD